Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 09, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 645,000 ordinary shares of 25 pence each.
- Purchase Price: 1,565.54 pence per share.
- Treasury Shares Held: 148,799,678 shares following the transaction.
- Shares in Issue: 5,820,930,665 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on March 09, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 25, 2005. The filing text does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying the 645,000 shares by the 1,565.54 pence price.
- Confirm the impact of the 148,799,678 Treasury shares on earnings per share (EPS) calculations.
- Review the full Annual General Meeting minutes from May 25, 2005, to understand the total authorized buyback limit.
- Check subsequent filings for the final disposition of the Treasury shares (cancellation vs. retention).